Chris practised as a microbiologist, project leader, and manager at Australia's premier pharmaceutical industry participant, CSL, for more than 25 years. During this time Chris's scientific work was recognised in peer reviewed publications, through an intellectual property portfolio successfully licensed for more than $20m, and by a young Tall Poppy Award from the AIPS.
Prior to signing the Bar Roll Chris completed a Juris Doctor at the University of Melbourne with a first class honours average and the Melbourne JD Dean's Award for the student placed first overall. Chris was awarded the Arthur Allens Award for Commercial Law, the Arnold Bloch Leibler Award for Corporations Law, the Blake Dawson Waldron Award for Trusts, the Middletons Award for Intellectual Property, the Clive Brookes Award for Legal Ethics, the Clayton Utz Award for Dispute Management (joint), the Minter Ellison Award for Torts, and the Dean's prizes for Comparative law, Constitutional Law, International Law, Legal Theory and Property Transactions.
Chris has a B.Sc. from the University of Melbourne, a Masters Degree in Biotechnology from Monash University and an MBA from Deakin/APESMA.
Chris's scientific career in the biotechnology industry has focussed on human and animal vaccine development and biopharmaceuticals. Following the discovery in Australia by Warren and Marshall of the bacterium responsible for peptic ulcers and gastric cancer (a discovery for which they were awarded the Nobel Prize in 2005) Chris initiated, then became Project Leader at CSL Limited of a project to develop a vaccine against the organism. This project involved a collaboration between scientists in Australia, Sweden and the United States. Chris was lead inventor on a patent portfolio developed during the project. Chris's managerial interests and experience focussed on the commercialisation of Australian biopharmaceutical research.
To get in touch with Chris Doidge | or for more information please contact the Clerk on: +61 3 9225 7222 or email@example.com